跳至主要内容
临床试验/EUCTR2016-001948-19-IT
EUCTR2016-001948-19-IT进行中(未招募)1 期

A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous Abatacept in Adults with Active Primary Sj¿grens Syndrome -

BRISTOL-MYERS SQUIBB INTERNATIONAL CORPORATIO0 个研究点目标入组 249 人开始时间: 2021年5月25日最近更新:
适应症
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
249

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • - ESSDAI score of at least 5
  • - Positive anti-SS-A/Ro antibody at screening
  • - Meet the proposed 2015 ACR/EULAR Classification Criteria for
  • Sjögren's Syndrome
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 287
  • F.1.3 Elderly (>=65 years) yes
  • F.1.3.1 Number of subjects for this age range 1

排除标准

  • - Secondary sjogrens syndrome
  • - Active life-threatening or organ-threatening complications of
  • Sjögren's-syndrome
  • - Other medical condition associated with sicca syndrome

研究者

相似试验